Harren Jhoti | |
---|---|
Born | 1962 (age 61–62) [1] |
Alma mater |
|
Known for | Astex Pharmaceuticals |
Awards | UK BioIndustry Association (BIA) Lifetime Achievement Award (2018) European Federation for Medicinal Chemistry Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery (2012) Royal Society of Chemistry Entrepreneur of the Year (2007) |
Scientific career | |
Fields | Drug discovery Structural biology |
Institutions | Astex University of Oxford |
Thesis | X-ray structural studies on transferrins (1989) |
Website | astx |
Harren Jhoti (born 1962 [1] ) is an Indian-born British structural biologist whose main interest has been rational drug design and discovery. [3] [4] He is president and chief executive officer (CEO) of biotechnology company Astex Pharmaceuticals ("Astex") which is located in Cambridge, United Kingdom.
Jhoti co-founded Astex with Tom Blundell and Chris Abell in 1999. [4] [5] He pioneered the development of fragment-based drug discovery (FBDD), [3] [6] [7] an approach now widely used in industry and academia, which identifies small molecules with potential therapeutic potential as part of the drug discovery process. Jhoti was Astex's chief scientific officer until November 2007 when he was appointed CEO. In 2013, Astex was acquired for around USD $900 million [8] and now operates as a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd, headquartered in Tokyo, Japan.
Prior to Astex, Jhoti was head of structural biology at GlaxoWellcome (now GSK). Before founding Astex in 1999, he was head of structural biology and bioinformatics at GlaxoWellcome in the UK (1991-1999). Prior to GlaxoWellcome, Jhoti was a post-doctoral scientist at the University of Oxford.[ citation needed ]
Jhoti received both his BSc (Hons) in biochemistry in 1985 and PhD in protein crystallography in 1989 from the University of London.
Jhoti's scientific achievements have been recognised by the Royal Society, [3] the Royal Society of Chemistry, the Royal Society of Biology and the Academy of Medical Sciences. [9] He has also received the UK BioIndustry Association (BIA)'s Lifetime Achievement Award (2018) [10] and the European Federation for Medicinal Chemistry's Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery (2012). [4] Jhoti has previously been recognised as the Royal Society of Chemistry's Entrepreneur of the Year Entrepreneur of the Year (2007). [5] He has also served on the board of the BIA between 2013-2015. [11]
Jhoti has been published in Nature and Science , and was featured in Time magazine after Astex was named a Technology Pioneer by the World Economic Forum in 2005. [12]
Jhoti was appointed Officer of the Order of the British Empire (OBE) in the 2023 New Year Honours for services to cancer research and drug discovery. [13]
The Wellcome Trust is a charitable foundation focused on health research based in London, United Kingdom. It was established in 1936 with legacies from the pharmaceutical magnate Henry Wellcome to fund research to improve human and animal health. The aim of the Trust is to "support science to solve the urgent health challenges facing everyone." It had a financial endowment of £29.1 billion in 2020, making it the fourth wealthiest charitable foundation in the world. In 2012, the Wellcome Trust was described by the Financial Times as the United Kingdom's largest provider of non-governmental funding for scientific research, and one of the largest providers in the world. According to their annual report, the Wellcome Trust spent GBP £1.1 billion on charitable activities across their 2019/2020 financial year. According to the OECD, the Wellcome Trust's financing for 2019 development increased by 22% to US$327 million.
Astex Pharmaceuticals is a biotechnology company focused on the discovery and development of drugs in oncology and diseases of the central nervous system. Astex was founded in 1999 by Sir Tom Blundell, Chris Abell & Harren Jhoti, and is located in Cambridge, England.
Steven Victor Ley is Professor of Organic Chemistry in the Department of Chemistry at the University of Cambridge, and is a Fellow of Trinity College, Cambridge. He was President of the Royal Society of Chemistry (2000–2002) and was made a CBE in January 2002, in the process. In 2011, he was included by The Times in the list of the "100 most important people in British science".
Dame Kay Elizabeth Davies is a British geneticist. She is Dr Lee's Professor of Anatomy at the University of Oxford and a Fellow of Hertford College, Oxford. She is director of the Medical Research Council (MRC) functional genetics unit, a governor of the Wellcome Trust, a director of the Oxford Centre for Gene Function, and a patron and Senior Member of Oxford University Scientific Society. Her research group has an international reputation for work on Duchenne muscular dystrophy (DMD). In the 1980s, she developed a test which allowed for the screening of foetuses whose mothers have a high risk of carrying DMD.
Sir David Keith Peters is a retired Welsh physician and academic. He was Regius Professor of Physic at the University of Cambridge from 1987 to 2005, where he was also head of the School of Clinical Medicine.
Dame Carol Vivien Robinson, is a British chemist and former president of the Royal Society of Chemistry (2018–2020). She was a Royal Society Research Professor and is the Dr Lee's Professor of Physical and Theoretical Chemistry, and a professorial fellow at Exeter College, University of Oxford. She is the founding director of the Kavli Institute for Nanoscience Discovery, University of Oxford, and she was previously professor of mass spectrometry at the chemistry department of the University of Cambridge.
Sheena Elizabeth Radford is a British biophysicist, and Astbury Professor of Biophysics and a Royal Society Research Professor in the Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology at the University of Leeds. Radford is the Associate Editor of the Journal of Molecular Biology.
Jane Clarke is a British biochemist and academic. Since October 2017, she has served as President of Wolfson College, Cambridge. She is also Professor of Molecular Biophysics, a Wellcome Trust Senior Research Fellow in the Department of Chemistry at the University of Cambridge. She was previously a Fellow of Trinity Hall, Cambridge. In 2023, she was elected to the National Academy of Sciences.
Benjamin Guy Davis is a British chemist who is Professor of Chemical biology in the Department of Pharmacology and a member of the Faculty in the Department of Chemistry at the University of Oxford and a Fellow of Pembroke College, Oxford. He holds the role of Science Director for Next Generation Chemistry (2019-2024) and Deputy Director (2020-) at the Rosalind Franklin Institute.
Melanie Georgina Lee CBE is an English pharmaceutical industry executive and CEO of LifeArc, succeeding Dave Tapolczay in November 2018.
David Chaim Rubinsztein FRS FMedSci is the Deputy Director of the Cambridge Institute of Medical Research (CIMR), Professor of Molecular Neurogenetics at the University of Cambridge and a UK Dementia Research Institute Professor.
Edith Yvonne Jones is a British molecular biologist who is director of the Cancer Research UK Receptor Structure Research Group at the University of Oxford and a Fellow of Jesus College, Oxford. She is widely known for her research on the molecular biology of cell surface receptors and signalling complexes.
Patrick John Thompson Vallance, Baron Vallance of Balham,, is a British physician, scientist, Life Peer, and clinical pharmacologist who serves as Minister of State for Science in the Department for Science, Innovation and Technology since July 2024. He previously served as HM Government chief scientific adviser from 2018 to 2023.
Jan Löwe is a German molecular and structural biologist and the Director of the Medical Research Council (MRC) Laboratory of Molecular Biology (LMB) in Cambridge, UK. He became Director of the MRC-LMB in April 2018, succeeding Sir Hugh Pelham. Löwe is known for his contributions to the current understanding of bacterial cytoskeletons.
Melissa Hanna-Brown is a British pharmacologist. She works for Pfizer UK and is a visiting professor at the University of Warwick.
Alan Frederick Cowman AC, FRS, FAA, CorrFRSE, FAAHMS, FASP, FASM is an internationally acclaimed malaria researcher whose work specialises in researching the malaria-causing parasite, Plasmodium falciparum, and the molecular mechanisms it uses to evade host responses and antimalarial drugs. As of May 2024, he is the deputy directory and Laboratory Head of the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, and his laboratory continues to work on understanding how Plasmodium falciparum, infects humans and causes disease. He was elected as a fellow of the Royal Society in 2011 and awarded the Companion of the Order of Australia in 2019 for his "eminent service to the biological sciences, notably to molecular parasitology, to medical research and scientific education, and as a mentor."
David Charles Rees CChem FRSC FMedSci is a chemist recognised internationally for his innovative use of chemistry in drug discovery. He is Chief Scientific Officer of biotechnology company Astex Pharmaceuticals, which is located in Cambridge, UK.
Gurdyal Singh Besra is a British scientist who is Bardrick Professor of Microbial Physiology & Chemistry at the University of Birmingham.
Alessio Ciulli is an Italian British biochemist. Currently, he is the Professor of Chemical & Structural Biology at the School of Life Sciences, University of Dundee, where he founded and directs Dundee' new Centre for Targeted Protein Degradation (CeTPD). He is also the scientific co-founder and advisor of Amphista Therapeutics.
Fiona Hamilton Marshall is a British pharmacologist, biotech-founder and President of Biomedical Research at Novartis. She founded and previously served as Chief Scientific Officer at Heptares Therapeutics, which was acquired by the Japanese biopharmaceutical company Sosei, where she served as Vice President. She was elected Fellow of the Academy of Medical Sciences in 2016 and the Royal Society in 2021.
"All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License." -- "Terms, conditions and policies | Royal Society". Archived from the original on 2016-11-11. Retrieved 2018-05-23.{{cite web}}
: CS1 maint: bot: original URL status unknown (link)
This article incorporates text available under the CC BY 4.0 license.